

## BRD4 Polyclonal Antibody

**CATALOG NO:** 6639-30T 30 µg (Trial size)  
6639-100 100 µg

**ALTERNATE NAMES:** BRD4, Protein HUWINK1, HUWINK1

**CONCENTRATION:** 0.5 mg/ml

**IMMUNOGEN:** Recombinant protein (Cat. No. 7644-20)

**INTERNAL ID:** BV-M58

**HOST:** Rabbit

**SPECIES REACTIVITY:** Human, Mouse, Rat

**PURIFICATION:** Affinity purified rabbit IgG


**FORMULATION:** Supplied in phosphate buffered saline (PBS), pH 7.2, containing 30% glycerol, 0.5% BSA, 5 mM EDTA and 0.03% proclin

**STORAGE CONDITIONS:** Store at -20°C. For long term storage, aliquot and freeze at -70°C. Avoid repeated freeze/thaw cycles.

**DESCRIPTION:** The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. The BET family of proteins, defined by tandem Bromodomains and an Extra Terminal domain, include BRD2, BRD3, BRD4, and BRDT. The BET proteins play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interactions. The isolated individual or tandem bromodomains of BRD2 and BRD4 have been shown to bind acetylated histone tails, serving to couple histone acetylation marks to the transcriptional regulation of target promoters. Small molecule inhibitors of these interactions hold promise as useful therapeutics for human disease..

**APPLICATION:** Western blotting: 1:200

**Note:** This information is only intended as a guide. The optimal dilutions must be determined by the user.



**Western blot of BRD4 antibody:**

Lane 1: BRD4 (342-460aa) 10 ng  
Lane 2: BRD4 (342-460aa) 150 ng  
Lane 2: BRD4 (342-460aa) 50 ng

### RELATED PRODUCTS:

- Recombinant Human BrdT (22-138 aa) (Cat. No. 7641-20, 100, -1000)
- Recombinant Human BRD4 (Cat. No. 7644-20, 100, -1000)
- Human recombinant BRD1 bromodomain (Cat. No. 7645-20, 100)
- Human recombinant BRD2 bromodomains 1 (Cat. No. 7646-20, 100)
- Human recombinant BRD2 bromodomain 1 and 2 (Cat. No. 7647-20, 100)
- Human recombinant BRD2 bromodomain 2 (Cat. No. 7648-20, 100)
- Human recombinant BRD9 bromodomain (Cat. No. 7649-20, 100)
- Bromodomain Inhibitor, (+)-JQ1 (Cat. No. 2070-1, -5)
- BRD8 Antibody (Cat. No. 3738-100)
- BRD8 Antibody (Cat. No. 3506-100)
- BRD8 Blocking Peptide (Cat. No. 3506BP-50)
- EZSolution™ (+)-JQ1 (Cat. No. 2091-1)
- I-BET151 (Cat. No. 2220-1, -5)
- PFI-1 (Cat. No. 2203-1, -5)

**FOR RESEARCH USE ONLY! Not to be used on humans.**